The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals ...

Panelists discuss how key biologic and clinical distinctions—such as ischemia, leakage patterns, and modality-specific ...

Panelists discuss how differing disease mechanisms, inflammatory drivers, and clinical priorities across AMD, DME, and RVO ...

EyePoint Pharmaceuticals' DURAVYU trials for wet AMD receive positive DSMC review, highlighting safety and potential for ...

Coave Therapeutics has announced its lead gene therapy program, CoTx-101, for the treatment of retinal vascular diseases, ...

Precise Bio has successfully treated a patient with PB-001, the company’s 3D-bio-printed corneal implant, at Rambam Medical ...

The trial is a phase 1/2 open-label, ascending-dose study of the safety and efficacy of OPGx-LCA5. Recently, the company ...

Foundation Fighting Blindness has granted public access to de-identified 4-year data from individuals participating in RUSH2A ...

The discussion explores how basal and reflex tears differ and why composition impacts sustained eye comfort.

Harrow has completed the acquisition of Melt Pharmaceuticals, which includes product candidates MELT-210, MELT-300, and ...

The central theme was moving beyond a lens-centric approach to vision, historically the foundation of presbyopia research, ...

A new treatment is presented that eliminates the root cause of the disease and restores ocular surface health.